Background: The variable efficacy (0-80%) of Mycobacterium bovis Bacille Calmette Gurein (BCG) vaccine against adult tuberculosis (TB) necessitates development of alternative vaccine candidates. Development of recombinant BCG (rBCG) over-expressing promising immunodominant antigens of M. tuberculosis represents one of the potential approaches for the development of vaccines against TB.
Loading...
Name
journal.pone.0003869.pdf
Type
Publisher's version
Access type
openaccess
Size
2.25 MB
Format
Adobe PDF
Checksum (MD5)
f81476037839a43b384cdae86d1345b6